What is Applied BioCode?
Applied BioCode is an innovative IVD manufacturer focused on the development and commercialization of multiplex testing products for clinical diagnostics. The company offers a comprehensive suite of assays, including panels for gastrointestinal and respiratory pathogens, alongside instruments engineered to boost laboratory efficiency. Their technology is designed for both clinical and research laboratories, enabling high-throughput testing and the simultaneous detection of multiple pathogens. Applied BioCode's solutions aim to streamline laboratory workflows and enhance patient care in the critical field of infectious disease diagnostics.
How much funding has Applied BioCode raised?
Applied BioCode has raised a total of $9.6M across 2 funding rounds:
Private Equity
$9.3M
Debt
$350K
Private Equity (2014): $9.3M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in Applied BioCode
PPP
Public-Private Partnership
What's next for Applied BioCode?
With a recent major strategic investment, Applied BioCode is poised for significant expansion and further product development. The company's focus on enhancing laboratory efficiency and providing advanced multiplex testing solutions positions it for continued growth in the competitive diagnostics market. Future endeavors will likely involve scaling production, expanding market reach, and potentially developing new assay panels to address emerging diagnostic needs. This strategic financing will be instrumental in accelerating their mission to improve infectious disease diagnostics.
See full Applied BioCode company page
